N/A N=118 Intensive Intervention for Toddlers With Autism (EARLY STEPS)
Autism · Autism Spectrum Disorder
Primary: Language Age Equivalent — 39.59; 36.09 language age in months — p=.03
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=20 Subthreshold Laser Treatment for Reticular Pseudodrusen and Geographic Atrophy Secondary to AMD
Age-Related Macular Degeneration · Geographic Atrophy · Reticular Pseudodrusen
Primary: Retinal Sensitivity — 12.08; 11.08; 11.45 dB — p=0.404
N/A N=42 High Intensity Interval Training Versus Circuit Training
High Intensity Interval Training
Primary: Maximal Oxygen Consumption (ml.Kg-1.Min-1) — 31.5; 31.4; 35.4; 32.4 ml/kg/min — p=<0.01
Phase 2 N=34 Sunitinib Malate in Treating Patients With Recurrent or Metastatic Endometrial Cancer
Endometrial Adenocarcinoma · Endometrial Endometrioid Adenocarcinoma · Endometrial Serous Adenocarcinoma
Primary: Objective Response Rate — 6; 6; 16; 5 Participants
Phase 2 N=12 H-22411: BOTOX® for Peyronie's Disease
Peyronie's Disease
Primary: Average Percent Change of Penile Curvature in Degrees — -21.73; 2.429 percent change — p=0.5154
Phase 2 N=205 Long Term Follow-up Study on Safety and Maintenance of Efficacy of ATX-101
Submental Fat · Healthy
Primary: Percentage of Participants Maintaining CR-SMFRS 1-Grade Response During 5 Years of Follow up, i.e. % of Participants Who Were CR-SMFRS 1-Grade Responders at Both…
Phase 3 N=506 Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer
Advanced Urothelial Carcinoma · Metastatic Bladder Urothelial Carcinoma · Metastatic Prostate Carcinoma
Primary: Overall Survival (OS) — 14.5; 14.3 months — p=0.1707
Phase 3 N=93 Safety Study of ATX-101 (Deoxycholic Acid) in Subjects With Mild or Extreme Fullness of Submental Fat
Moderate to Severe Convexity of Submental Fat · Safety · Efficacy
Primary: Percentage of Participants With at Least a 1-Grade Reduction (Improvement) at 12 Weeks From Last Treatment Based on Both the Clinician-Reported Submental Fat Rating…
Phase 3 N=324 Efficacy and Safety of Oral Semaglutide Versus Placebo in Subjects With Type 2 Diabetes and Moderate Renal Impairment
Diabetes · Diabetes Mellitus, Type 2
Primary: Change in HbA1c — -1.1; -0.2; -1.2; -0.1 Percentage of HbA1c — p=<0.0001
N/A N=297 Nasopharyngeal Carriage Study in Healthy Kenyan Toddlers
Pneumococcal Disease
Primary: Prevalence of Streptococcus Pneumoniae in Nasopharynx — 76; 43; 86; 46 Participants
Phase 3 N=224 Long-term Follow-up Study on Safety and Maintenance of Efficacy of ATX-101
Submental Fat · Healthy
Primary: Percentage of Participants Maintaining CR-SMFRS 1-Grade Response During 3 Years of Follow up, i.e. % of Participants Who Were CR-SMFRS 1-Grade Responders at Both…
Phase 2 N=26 Thymus Transplantation in DiGeorge Syndrome #668
DiGeorge Syndrome · Complete Typical DiGeorge Anomaly
Primary: Survival at 1 Year Post-Cultured Thymus Tissue Implantation (CTTI) — 72 % of participants who survive to 1 year
Phase 4 N=80 Femoral Versus Adductor Canal Continuous Peripheral Nerve Blocks for Knee Arthroplasty
Postoperative Pain Following Knee Arthroplasty
Primary: Hours Until Discharge Readiness — 61; 55 hours
N/A N=108 Cognitive and Emotional Skills to Aid Smoking Prevention
Tobacco Smoking
Primary: Specific Aim 1: Percentage of Participants Who Attended 13 or More Interventions — 41.0; 50; 40.5 percentage of participants
Phase 3 N=882 A Study of Pembrolizumab (MK-3475) for First Line Treatment of Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck (MK-3475-048/KEYNOTE-048)
Recurrent Head and Neck Cancer · Metastatic Head and Neck Cancer
Primary: Pembro Combo vs Control: Progression Free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) by Blinded Independent Central Review…